Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Dexcom (DXCM) Net Margin (2016 - 2025)

Dexcom (DXCM) has disclosed Net Margin for 16 consecutive years, with 21.22% as the latest value for Q4 2025.

  • On a quarterly basis, Net Margin rose 760.0% to 21.22% in Q4 2025 year-over-year; TTM through Dec 2025 was 17.94%, a 365.0% increase, with the full-year FY2025 number at 17.94%, up 365.0% from a year prior.
  • Net Margin was 21.22% for Q4 2025 at Dexcom, down from 23.47% in the prior quarter.
  • In the past five years, Net Margin ranged from a high of 24.78% in Q4 2023 to a low of 6.55% in Q1 2023.
  • A 5-year average of 13.93% and a median of 13.42% in 2024 define the central range for Net Margin.
  • Peak YoY movement for Net Margin: crashed -6421bps in 2021, then surged 1351bps in 2023.
  • Dexcom's Net Margin stood at 8.09% in 2021, then skyrocketed by 39bps to 11.26% in 2022, then surged by 120bps to 24.78% in 2023, then tumbled by -45bps to 13.62% in 2024, then surged by 56bps to 21.22% in 2025.
  • Per Business Quant, the three most recent readings for DXCM's Net Margin are 21.22% (Q4 2025), 23.47% (Q3 2025), and 15.54% (Q2 2025).